Jamison Private Wealth Management Inc. Has $2.52 Million Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Jamison Private Wealth Management Inc. cut its stake in Bristol Myers Squibb Company (NYSE:BMY) by 5.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,315 shares of the biopharmaceutical company’s stock after selling 2,159 shares during the period. Jamison Private Wealth Management Inc.’s holdings in Bristol Myers Squibb were worth $2,520,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new position in Bristol Myers Squibb in the 4th quarter valued at $25,000. Park Square Financial Group LLC acquired a new position in Bristol Myers Squibb in the 4th quarter valued at $26,000. Fairway Wealth LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $28,000. Transce3nd LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $28,000. Finally, Global Wealth Strategies & Associates increased its stake in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 275 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BMY has been the topic of several recent analyst reports. Argus upgraded Bristol Myers Squibb to a “hold” rating in a research note on Friday, April 25th. William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. UBS Group decreased their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research note on Friday, April 11th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $58.00.

Bristol Myers Squibb Trading Up 0.1%

NYSE BMY opened at $46.87 on Friday. The business’s 50-day moving average price is $48.20 and its two-hundred day moving average price is $54.35. Bristol Myers Squibb Company has a 12 month low of $39.35 and a 12 month high of $63.33. The firm has a market capitalization of $95.38 billion, a PE ratio of 17.55, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business’s revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($4.40) EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.29%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio is 92.88%.

Insider Activity

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company’s stock in a transaction dated Friday, April 25th. The shares were bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.